| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/20/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 07/18/2022 | 168.29% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 04/28/2022 | 143.9% | Chardan Capital | → $5 | Initiates Coverage On | → Buy |
| 06/03/2021 | 241.46% | Roth Capital | $5 → $7 | Maintains | Buy |
| 01/28/2021 | 95.12% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 04/17/2020 | 46.34% | Oppenheimer | $2 → $3 | Maintains | Outperform |
| 06/27/2019 | -2.44% | Oppenheimer | → $2 | Initiates Coverage On | → Outperform |
| 10/15/2018 | 46.34% | HC Wainwright & Co. | $3 → $3 | Upgrades | Neutral → Buy |
| 03/09/2018 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 03/08/2018 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral |
Vascular Biogenics Questions & Answers
The latest price target for Vascular Biogenics (NASDAQ: VBLT) was reported by HC Wainwright & Co. on July 20, 2022. The analyst firm set a price target for $0.00 expecting VBLT to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Vascular Biogenics (NASDAQ: VBLT) was provided by HC Wainwright & Co., and Vascular Biogenics downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vascular Biogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vascular Biogenics was filed on July 20, 2022 so you should expect the next rating to be made available sometime around July 20, 2023.
While ratings are subjective and will change, the latest Vascular Biogenics (VBLT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Vascular Biogenics (VBLT) is trading at is $2.05, which is out of the analyst's predicted range.